Form 4: BDTX Executive Granted 200,000 Stock Options

Black Diamond Therapeutics' Senior VP of Finance, Erika Jones, was granted 200,000 stock options with an exercise price of $2.57, vesting over four years.

Summary

• Erika Jones, Senior Vice President, Finance and Corporate Controller of Black Diamond Therapeutics, Inc. (BDTX), was granted 200,000 stock options.
• The options have an exercise price of $2.57 per share.
• The transaction date for the grant was January 21, 2026.
• The options will vest with 25% becoming exercisable on January 21, 2027, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• The expiration date for these options is January 20, 2036.
• Vesting is contingent upon Ms. Jones's continued service to the company.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive sign for executive retention and alignment of interests with shareholders. It reflects standard compensation practices and does not indicate any immediate negative operational or financial issues for the company.

Positives

• The grant of 200,000 stock options to a key executive, Erika Jones, aligns her long-term interests with those of shareholders.
• Equity compensation is a standard practice for retaining and incentivizing senior management.

Negatives

• No direct negatives are presented in this Form 4 filing, which is a disclosure of an equity grant.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The vesting schedule for the stock options, extending until January 2027 for the initial tranche and then monthly for three years, indicates an expectation of Erika Jones's continued service and commitment to Black Diamond Therapeutics' long-term performance.

Industry Context

The grant of stock options to a Senior Vice President is a common practice in the biotechnology and pharmaceutical industries, used to attract, retain, and motivate key executives by linking their compensation to the company's stock performance and long-term success. This aligns executive incentives with shareholder value creation.

Comparison to Industry Standards

• Equity grants, such as stock options, are a standard component of executive compensation packages across the biotechnology and pharmaceutical sectors, comparable to practices at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which frequently use similar mechanisms to incentivize leadership.
• The vesting schedule, typically over three to four years, is also consistent with industry norms designed to encourage long-term commitment and performance from executives.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value creation.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• Erika Jones's continued service to Black Diamond Therapeutics to fulfill vesting conditions.
• Potential future exercise of options by Erika Jones, subject to vesting and market conditions.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Stock Options, Executive Compensation, Insider Transaction, Erika Jones, Equity Grant, Form 4